Company Profile
H. Lundbeck provides the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders globally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults.
Its portfolio also includes Brintellix/Trintellix to treat depressive disorders, Rexulti/Rxulti to treat major depressive disorder and schizophrenia, Vyepti for migraine prevention, and Cipralex/Lexapro for depression Northera for symptomatic neurogenic orthostatic hypotension.
Its portfolio also includes Onfi for epilepsy, Sabril for refractory complex partial seizures and infantile spasms, Ebixa for dementia, Azilect for Parkinson's disease, Xenazine for chorea, Deanxit for depression, Cipramil for depression and anxiety, and Cisordinol for psychosis. Additionally, it develops Eptinezumab for migraine prevention.
Its portfolio also includes Eptinezumab, which is in phase 3 clinical trial for cluster headache, Lu AG09222, which is in phase 2 clinical trial for migraine prevention, Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions, Brexpiprazole for post-traumatic stress disorder, Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease, MAGLi program that is in phase 1 clinical trial for neurology, Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies, Amlenetug that is in phase 3 clinical trial for synucleinopathies, and Lu AG22515, which is in clinical phase 1 clinical trial for neurology.
Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. Founded in 1915, the company is headquartered in Valby, Denmark.